AU474405B2 - Rapamycin and process of preparation - Google Patents

Rapamycin and process of preparation

Info

Publication number
AU474405B2
AU474405B2 AU60447/73A AU6044773A AU474405B2 AU 474405 B2 AU474405 B2 AU 474405B2 AU 60447/73 A AU60447/73 A AU 60447/73A AU 6044773 A AU6044773 A AU 6044773A AU 474405 B2 AU474405 B2 AU 474405B2
Authority
AU
Australia
Prior art keywords
rapamycin
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU60447/73A
Other languages
English (en)
Other versions
AU6044773A (en
Inventor
FEODORA MILICA BLAZEKOVIC and CLAUDE VEZINA SURENDRA NATH SEHGAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Canada Inc
Original Assignee
Ayerst Mckenna and Harrison Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayerst Mckenna and Harrison Inc filed Critical Ayerst Mckenna and Harrison Inc
Publication of AU6044773A publication Critical patent/AU6044773A/en
Application granted granted Critical
Publication of AU474405B2 publication Critical patent/AU474405B2/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/898—Streptomyces hygroscopicus

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU60447/73A 1972-09-29 1973-09-19 Rapamycin and process of preparation Expired AU474405B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29369972A 1972-09-29 1972-09-29
USUS293699 1972-09-29

Publications (2)

Publication Number Publication Date
AU6044773A AU6044773A (en) 1975-03-20
AU474405B2 true AU474405B2 (en) 1976-07-22

Family

ID=23130177

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60447/73A Expired AU474405B2 (en) 1972-09-29 1973-09-19 Rapamycin and process of preparation

Country Status (21)

Country Link
US (1) US3929992A (forum.php)
AR (1) AR197832A1 (forum.php)
AU (1) AU474405B2 (forum.php)
BE (1) BE805505A (forum.php)
CA (1) CA1000631A (forum.php)
CH (1) CH591558A5 (forum.php)
CS (1) CS185630B2 (forum.php)
DD (1) DD107070A5 (forum.php)
DE (1) DE2347682C2 (forum.php)
DK (1) DK134607B (forum.php)
ES (1) ES419160A1 (forum.php)
FR (1) FR2201076B1 (forum.php)
GB (1) GB1436447A (forum.php)
HK (1) HK51079A (forum.php)
HU (1) HU166346B (forum.php)
IE (1) IE38267B1 (forum.php)
IN (1) IN139114B (forum.php)
NL (1) NL175641C (forum.php)
SE (1) SE399437B (forum.php)
YU (1) YU37358B (forum.php)
ZA (1) ZA737247B (forum.php)

Families Citing this family (395)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069316A (en) * 1976-11-01 1978-01-17 Takeda Chemical Industries, Ltd. Method for producing antibiotic T-42082 and antibiotic T-42082
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4230692A (en) * 1978-11-03 1980-10-28 Ayerst Mckenna & Harrison, Inc. Ravidomycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
AU543727B2 (en) 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4375464A (en) * 1981-11-19 1983-03-01 Ayerst, Mckenna & Harrison Inc. Antibiotic AY24,668 and process of preparation
AR240943A1 (es) * 1985-02-05 1991-03-27 Sankio Company Limited Nuevo compuesto agroquimico denominado "sustancia n*51262" procedimiento para prepararlo y composicion que lo comprende"
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5120726A (en) * 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5358944A (en) * 1990-09-19 1994-10-25 American Home Products Corporation Rapamycin esters for treating transplantation rejection
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5130307A (en) * 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5776943A (en) * 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
ATE135583T1 (de) 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5221740A (en) * 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
EP0562853B1 (en) 1992-03-27 1996-06-05 American Home Products Corporation 29-Demethoxyrapamycin for inducing immunosuppression
JPH07505628A (ja) * 1992-03-30 1995-06-22 アメリカン・ホーム・プロダクツ・コーポレイション 静脈注射用のラパマイシン製剤
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
GB9302569D0 (en) * 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
CA2161101A1 (en) 1993-04-23 1994-11-10 Eduardo Gonzalez Rapamycin conjugates and antibodies
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB9315914D0 (en) * 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
MY129435A (en) 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5606222A (en) * 1994-12-29 1997-02-25 Philips Electronics North America Corporation Lighting system with a device for reducing system wattage
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US7282220B1 (en) 1996-11-05 2007-10-16 Hsing-Wen Sung Genipin-crosslinked gelatin microspheres as drug carrier
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
EP1857113A3 (en) 1997-10-22 2007-12-19 Jens Ponikau USE OF ANTIFUNGAL AGENTS FOR THE TOPICAL TREATMENT OF asthma
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US7960405B2 (en) * 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6573074B2 (en) 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7419678B2 (en) * 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1319008B1 (en) 2000-09-19 2008-10-15 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
WO2002026139A1 (en) 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
EP1419154B1 (en) 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US7195640B2 (en) 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20050020614A1 (en) * 2002-01-10 2005-01-27 Prescott Margaret Forney Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20030204168A1 (en) 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US20070083258A1 (en) 2005-10-06 2007-04-12 Robert Falotico Intraluminal device and therapeutic agent combination for treating aneurysmal disease
US7300942B2 (en) 2002-07-16 2007-11-27 Biotica Technology Limited Production of polyketides and other natural products
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
BR0314013A (pt) 2002-09-06 2005-07-12 Abbott Lab Equipamento médico contendo inibidor de hidratação
WO2004022767A1 (en) * 2002-09-09 2004-03-18 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
KR20050084559A (ko) * 2002-09-17 2005-08-26 와이어쓰 경구 제형
US20050038504A1 (en) * 2003-01-22 2005-02-17 Harry Halleriet Kit for applying drug coating to a medical device in surgeon room
US6919100B2 (en) * 2003-01-22 2005-07-19 Cordis Corporation Method for coating medical devices
US8318235B2 (en) * 2003-01-22 2012-11-27 Cordis Corporation Method for applying drug coating to a medical device in surgeon room
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US20040167572A1 (en) * 2003-02-20 2004-08-26 Roth Noah M. Coated medical devices
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7527632B2 (en) * 2003-03-31 2009-05-05 Cordis Corporation Modified delivery device for coated medical devices
UA80756C2 (en) * 2003-04-22 2007-10-25 Wyeth Corp Antineoplastic combinations of rapomicine and interferon alfa (?) in the treatment of neoplasms
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20040236416A1 (en) * 2003-05-20 2004-11-25 Robert Falotico Increased biocompatibility of implantable medical devices
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20050033417A1 (en) 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
US20050137677A1 (en) 2003-12-17 2005-06-23 Rush Scott L. Endovascular graft with differentiable porosity along its length
US8652502B2 (en) * 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US20050249776A1 (en) * 2003-12-19 2005-11-10 Chen Chao C Coated aneurysmal repair device
US8747881B2 (en) 2003-12-19 2014-06-10 Cordis Corporation Intraluminal medical devices in combination with therapeutic agents
EP1701698B1 (en) * 2004-01-08 2008-01-16 Wyeth a Corporation of the State of Delaware Directly compressible pharmaceutical composition for the oral admimistration of cci-779
US7303758B2 (en) 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
US7806924B2 (en) * 2004-02-18 2010-10-05 Cordis Corporation Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
EP1568394A1 (en) 2004-02-26 2005-08-31 Muijs van de Moer, Wouter Matthijs Coated electrode
US8828416B2 (en) 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
CA2559747C (en) * 2004-03-19 2013-12-31 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US7875282B2 (en) * 2004-03-22 2011-01-25 Cordis Corporation Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
CA2562805C (en) * 2004-04-12 2014-03-11 Biocon Limited Process for the production of macrolides using a novel strain, streptomyces sp. bicc 7522
WO2005105811A1 (en) 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
BRPI0509854A (pt) 2004-04-14 2007-10-23 Wyeth Corp composto, métodos para a preparação regio-especìfica de um 42-éster de rapamicina ou 42-éster de prolina-rapamicina e para a preparação de um 42-éster de prolina-rapamicina, composição, e, produto
US8007737B2 (en) 2004-04-14 2011-08-30 Wyeth Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
CA2562962A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
AU2005238493A1 (en) * 2004-04-27 2005-11-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
AR050374A1 (es) * 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
JP5117190B2 (ja) * 2004-08-27 2013-01-09 コーディス・コーポレイション 溶媒を含有しない非晶質ラパマイシン
CN101031653A (zh) * 2004-09-10 2007-09-05 伊瓦克斯制药有限公司 大环内酯化合物的分离方法
BRPI0515695A (pt) * 2004-09-10 2008-03-04 Ivax Pharmaceuticals Sro processo para isolamento de tacrolimus cristalino
AU2005284422A1 (en) * 2004-09-16 2006-03-23 Bayer Healthcare Ag Dermally applicable formulations for treating skin diseases in animals
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
WO2006039237A1 (en) * 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20060129225A1 (en) * 2004-12-15 2006-06-15 Kopia Gregory A Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium
GB0503936D0 (en) * 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
EP3138531A1 (en) 2005-03-23 2017-03-08 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
EP2327429B1 (en) 2005-03-23 2014-09-17 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
KR101492545B1 (ko) * 2005-07-15 2015-02-12 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007011707A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
EP2586798A3 (en) 2005-07-25 2013-08-07 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US20070026042A1 (en) * 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease
US20070048350A1 (en) * 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
JPWO2007037544A1 (ja) * 2005-09-30 2009-04-16 国立大学法人京都大学 制御性ｔ細胞の製造を向上させる薬剤のスクリーニング方法の開発、及び免疫抑制性のマクロライド系抗生剤を用いる制御性ｔ細胞の製造方法
US8784860B2 (en) * 2005-10-27 2014-07-22 Cordis Corporation Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
US20070173787A1 (en) * 2005-11-01 2007-07-26 Huang Mark C T Thin-film nitinol based drug eluting stent
US20070116736A1 (en) 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US20070128242A1 (en) * 2005-12-01 2007-06-07 Zhao Jonathan Z Polymeric compositions for controlled release or delivery of pharmacologically active agents
AR058283A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) * 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
EP2944382A1 (en) 2006-04-26 2015-11-18 Micell Technologies, Inc. Coatings containing multiple drugs
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
CA2656112A1 (en) * 2006-06-30 2008-05-08 Hanje Chen Bioresponsive polymers
US8506984B2 (en) * 2006-07-26 2013-08-13 Cordis Corporation Therapeutic agent elution control process
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) * 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2431036B1 (en) 2006-09-13 2017-04-12 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
US20080097591A1 (en) * 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
EP2111184B1 (en) 2007-01-08 2018-07-25 Micell Technologies, Inc. Stents having biodegradable layers
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
US20090281059A1 (en) 2007-02-21 2009-11-12 Robert Falotico Coating for a medical device having an anti-thrombotic conjugate
US20080241215A1 (en) 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
CA2688314C (en) 2007-05-25 2013-12-03 Micell Technologies, Inc. Polymer films for medical device coating
US20090068266A1 (en) * 2007-09-11 2009-03-12 Raheja Praveen Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090130210A1 (en) * 2007-09-11 2009-05-21 Raheja Praveen Pharmaceutical compositions of sirolimus
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
EP2203498B1 (en) 2007-10-05 2017-12-06 Interface Biologics Inc. Oligofluorinated cross-linked polymers and uses thereof
ES2623456T3 (es) 2007-10-19 2017-07-11 Interface Biologics Inc. Recubrimientos autoeliminantes
AU2008318560B2 (en) 2007-10-31 2014-12-04 Cardinal Health 529, Llc Method of making a vascular closure device
US9603980B2 (en) 2008-02-26 2017-03-28 CARDINAL HEALTH SWITZERLAND 515 GmbH Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
MX350637B (es) 2008-04-17 2017-09-11 Micell Technologies Inc Stents que tienen capas bioabsorbibles.
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
JP5748659B2 (ja) 2008-06-10 2015-07-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTONE COMPOUNDS AND METHODS OF USE
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
CN104042612A (zh) 2008-11-11 2014-09-17 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
PA8855601A1 (es) * 2008-12-23 2010-07-27 Forformidatos de nucleósidos
NZ617066A (en) * 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
WO2010075554A1 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20120231037A1 (en) * 2009-02-02 2012-09-13 Yissum Research Development Companyof the Hebrew U Crystalline drug-containing coatings
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
US8492110B2 (en) 2009-04-10 2013-07-23 Haiyan Qi Anti aging agents and methods to identify them
US20100268187A1 (en) * 2009-04-17 2010-10-21 Ranbaxy Laboratories Limited Packaging for sirolimus and composition thereof
US20100280600A1 (en) 2009-04-30 2010-11-04 Vipul Bhupendra Dave Dual drug stent
US20110137407A1 (en) * 2009-07-09 2011-06-09 Thai Minh Nguyen Bare metal stent with drug eluting reservoirs
US9327060B2 (en) * 2009-07-09 2016-05-03 CARDINAL HEALTH SWITZERLAND 515 GmbH Rapamycin reservoir eluting stent
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
WO2011053938A1 (en) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2506716B1 (en) 2009-12-01 2017-05-17 AbbVie Inc. Novel tricyclic compounds
KR20120102724A (ko) * 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
WO2011128910A2 (en) 2010-03-02 2011-10-20 Rpg Life Sciences Limited A drug delivery solid dosage formulation of sirolimus
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
US20120130481A1 (en) 2010-11-18 2012-05-24 Robert Falotico Local vascular delivery of adenosine a2a receptor agonists in combination with other agents to reduce myocardial injury
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN102372726B (zh) * 2011-11-08 2014-02-19 福建省微生物研究所 西罗莫司粗晶的制备方法
CN102433364B (zh) * 2011-11-10 2013-10-23 中科医药行业生产力促进中心有限公司 一种微生物发酵法制取雷帕霉素的工艺
EP2594260A1 (en) 2011-11-18 2013-05-22 LEK Pharmaceuticals d.d. Solid preparations comprising sirolimus with desired bioavailability and method for its preparation
EP2790723A1 (en) 2011-12-16 2014-10-22 Pfizer Inc Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2013153554A1 (en) 2012-04-12 2013-10-17 Natco Pharma Limited Fermentation process for the production of rapamycin
DK2859001T3 (da) 2012-06-08 2016-05-30 Biotronik Ag Rapamycin 40-o-cyklisk kulbrinteestere, sammensætninger og fremgangsmåder
US9278090B2 (en) 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
WO2014072984A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Improved process for isolation and purification of rapamycin from fermentation broth
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
JP6330024B2 (ja) 2013-03-12 2018-05-23 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
KR20180059584A (ko) 2013-05-15 2018-06-04 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US20150265582A1 (en) 2014-02-11 2015-09-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
MX394266B (es) 2014-04-04 2025-03-24 Ai Therapeutics Inc Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
WO2015157252A1 (en) 2014-04-07 2015-10-15 BROGDON, Jennifer Treatment of cancer using anti-cd19 chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016014576A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
EP3193902A4 (en) 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
US10603325B2 (en) 2014-10-29 2020-03-31 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
US20190054117A1 (en) 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CN104844620B (zh) * 2015-04-10 2018-06-19 鲁南新时代生物技术有限公司 一种雷帕霉素的分离纯化方法
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2986359A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
AU2016315653A1 (en) * 2015-08-28 2018-03-15 Buck Institute For Research On Aging Rapamycin analogs showing improved mTORC1 specificity
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120289468A (zh) 2015-10-16 2025-07-11 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017081624A1 (en) 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
US10441584B2 (en) 2016-11-23 2019-10-15 Novartis Ag Methods of enhancing immune response
CN110603038A (zh) 2017-02-10 2019-12-20 塔姆山治疗公司 雷帕霉素类似物
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3644997A1 (en) 2017-06-26 2020-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of olmsted syndrome
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP4234031A3 (en) 2018-05-01 2024-02-28 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
KR20210020932A (ko) 2018-06-13 2021-02-24 노파르티스 아게 Bcma 키메라 항원 수용체 및 이의 용도
JP2022510573A (ja) 2018-07-23 2022-01-27 エンクリアー セラピーズ， インク． 神経障害の治療方法
EP3826650A4 (en) 2018-07-23 2022-07-27 Enclear Therapies, Inc. METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
EP3849545A1 (en) 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of neurofibromatosis
SI3898637T1 (sl) 2018-12-18 2025-04-30 Novartis Ag Derivati rapamicina
MX2021011376A (es) 2019-03-26 2021-10-13 Novartis Ag Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos.
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
EP4221801A4 (en) 2020-09-29 2024-11-06 Enclear Therapies, Inc. METHOD AND SYSTEM FOR MANAGING SUBARACHNOID FLUID
AU2020277132B1 (en) 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition
US20220409567A1 (en) * 2021-06-23 2022-12-29 Thomas Winston Adjuvant and complementary therapies for the treatment of cancer
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
JP2025521677A (ja) 2022-07-06 2025-07-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 増殖性糸球体腎炎を処置するための方法
EP4565217A1 (en) 2022-08-04 2025-06-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2024211738A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof

Also Published As

Publication number Publication date
CA1000631A (en) 1976-11-30
IE38267L (en) 1974-03-29
GB1436447A (en) 1976-05-19
AU6044773A (en) 1975-03-20
CS185630B2 (en) 1978-10-31
BE805505A (fr) 1974-03-28
YU37358B (en) 1984-08-31
NL175641B (nl) 1984-07-02
DD107070A5 (forum.php) 1974-07-12
DK134607C (forum.php) 1977-05-16
FR2201076A1 (forum.php) 1974-04-26
CH591558A5 (forum.php) 1977-09-30
FR2201076B1 (forum.php) 1977-09-09
IN139114B (forum.php) 1976-05-08
US3929992A (en) 1975-12-30
HU166346B (forum.php) 1975-03-28
NL7313386A (forum.php) 1974-04-02
DE2347682C2 (de) 1984-08-02
SE399437B (sv) 1978-02-13
ES419160A1 (es) 1976-06-16
ZA737247B (en) 1975-04-30
DK134607B (da) 1976-12-06
AR197832A1 (es) 1974-05-10
HK51079A (en) 1979-08-03
YU246473A (en) 1983-04-27
NL175641C (nl) 1984-12-03
DE2347682A1 (de) 1974-04-11
IE38267B1 (en) 1978-02-01

Similar Documents

Publication Publication Date Title
AU474405B2 (en) Rapamycin and process of preparation
CA984388A (en) Benzodiazepine derivatives and process of making them
AU474015B2 (en) Salt ofs-adenosil-l-methionine and process of preparation
CA1001475A (en) Gluten-lipid complexes and process of preparation
AU467524B2 (en) Composition of matter and process
AU474519B2 (en) Process forthe preparation of thiazolesulphenamides
AU474118B2 (en) Process forthe preparation of 3-cyanpchromones
CA1020560A (fr) Procede de preparation d'hydrazones
CA1014161A (fr) Procede de preparation de thiazolsulfenamides
AU470296B2 (en) Antibiotic a-2315 and process for preparation thereof
AU467625B2 (en) New amino-propane derivatives and processes for their preparation
CA1026334A (en) Nitroimidazolyl-triazolo-pyridazines and process for their preparation
CA1013739A (en) Everninomicin derivatives and process for their preparation
CA905973A (en) Derivatives of 3-aryl-5-methylhydantoins and process for their preparation
CA903942A (en) Polyxylylidenes and method of preparation
CA994775A (en) Benzoquinolizine derivatives and process for their preparation and use
CA912746A (en) Solid polyperfluorostyrene and method of preparation
CA890418A (en) Derivative of tyrosinol and preparation thereof
CA913085A (en) Isoxazolidine derivatives and their method of preparation
CA917143A (en) Cardio-active oxy-esters of steroid-cardenolides and sterioid-bufadienolides and process for their manufacture
CA891507A (en) Nitroimidazoloyl derivatives and method of preparing
CA896579A (en) Amino-ketones and process for their preparation
CA892611A (en) Ketonitriles and process for their preparation
AU479066B2 (en) Novel everninomicin derivatives and process for their preparation
CA891261A (en) Stocking and method of making same